Months into booming acute migraine launch, Biohaven chases prevention with oral CGRP med Nurtec ODT
In the suddenly bustling market for CGRP acute migraine fighters, Biohaven has touted its Nurtec ODT as an obvious choice for patients with its fast dissolving oral formulation. Despite hitting the oral market second, Nurtec is keeping pace with its immediate rival and is angling for even bigger fish in prevention.
In Phase III data published Tuesday in The Lancet, Biohaven’s Nurtec cut patient’s average migraine days by 4.3 per month compared with placebo and sliced the number of moderate-to-severe migraines per month by more than 50%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.